Home » ISPOR Posters » Are NICE Appraisal Committees being consistent in their implementation of the end of life criterion?
Most Recent Articles
Efficacy of CFTR modulators against pulmonary exacerbation in cystic fibrosis
Landscape assessment and key HTA considerations in Alzheimer’s disease
The chronic obstruction to COPD market access
Somatostatin analogues in imaging of breast cancer
Estimating the burden of malignant haematopoietic cancers in Nordic countries
Estimating the burden of salivary gland cancer in Nordic countries
Vaccine reimbursement trends and associated challenges in Europe
Abbreviated HTA pathways, expediting patient access to novel treatments
Pan-EU clinical HTA – a differential and non-uniform impact?
The not-NICE access pathway: NHS England specialised commissioning
Reimbursement of ultra-orphan medicines
A simple strategy to improve additional benefit outcomes in Germany?
The HST test: good, better, best?
Are there regional variations in HTA outcomes for combination products involving two vs. one manufacturer?
Unlocking access for transformational CAR-T cell and gene therapies
Have EMA prime designations supported accelerated regulatory approval and patient access?
Will CAR-T cell therapies change how drugs are priced and reimbursed?
Do Spanish TPRs affect the national pricing and reimbursement of drugs?
Keeping the ROI window open